• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Lupin receives FDA approval for generic Clobex lotion

expressbpdSeptember 27, 2017

Tag: lupin , FDA , Clobex lotion

It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations

Lupin has received final approval for its Clobetasol Propionate Lotion, 0.05 per cent from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories’ Clobex lotion, 0.05 per cent.

Lupin’s Clobetasol Propionate Lotion, 0.05 per cent is the AB rated generic equivalent of Galderma Laboratories’ Clobex lotion, 0.05 per cent. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.

Previous:Clariant launches Amide/Amine-Free Anti-Static Concentrate for clean-room and API films

Next:Mithra and Libbs partner to commercialise Estelle oral contraceptive in Brazil

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Lupin receives FDA approval for generic Clobex lotion | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

filter integrity testing fda guidelines

filter integrity testing fda guidelines
Fluorfenicol( FDA)

Fluorfenicol( FDA)
Etoposide( FDA)

Etoposide( FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Tobramycin base( FDA)

Tobramycin base( FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Lupeol-98%-Lupinus Albus Extracts

Lupeol-98%-Lupinus Albus Extracts

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service